Immunohistochemistry/IHC Market worth $2.7 billion by 2025

The report Immunohistochemistry/IHC Market by Product (Antibodies, Reagents (Chromogenic Substrates), Kits), Application (Diagnostics (Cancer, Infectious), Research, Forensic), End User (Hospitals, Diagnostic Laboratories, Academic) – Global Forecast to 2025″, is projected to reach USD 2.7 billion by 2025 from USD 1.9 billion in 2020, at a CAGR of 6.6% during the forecast period. The increasing incidence and prevalence of cancer, technological advancements in IHC, and the availability of reimbursement for IHC tests are the major factors driving the growth of this market.

Browse 247 market data Tables and 28 Figures spread through 236 Pages and in-depth TOC on “Immunohistochemistry/IHC Market  – Global Forecast to 2025”

Get a Sample Pages of report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=121632939

The cancer segment accounted for the largest share of the diagnostic segment in the IHC market

Based on diseases, the diagnostic applications is further segmented into infectious diseases, cancer, autoimmune diseases, neurology, nephrological diseases, and other diseases (cardiovascular diseases, ophthalmology, and diabetes). In 2019, the cancer diagnostics segment accounted for the largest share  of the immunohistochemistry market for diagnostic applications Growing use of IHC tests for cancer diagostics and increasing prevalence & incidence of cancer to fuel market growth.

Opportunity: Increasing demand for personalized medicine

Personalized medicine for non-small-cell lung cancer patients has proven to be extremely effective, and its use is expected to increase in the future. Immunohistochemistry techniques support this approach to treatment decision-making by performing the most complete and accurate histological subtyping of tumors possible (supported by predictive immunohistochemistry and the assessment of relevant biomarkers). Moreover, the increased availability of immunohistochemistry assays that detect mutant proteins (e.g., BRAF V600E and IDH1 R132H) provides a helpful replacement and/or adjunct for molecular testing. These techniques are highly reproducible, entail reasonable technical and interpretation complexity, and are available at relatively lesser costs, making them valuable novel tools in modern cancer care. The development of multiplex and mutation-specific immunohistochemistry assays represents important innovations, which provide improved utility in the context of personalized medicine and targeted therapy. The PD-L1 IHC assay is currently being used in late-stage nivolumab clinical studies for multiple indications, including non-small-cell lung cancer.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121632939

North America accounted for the largest share of the IHC market

North America accounted for the largest share of the IHC market, followed by Europe in 2019. The growth in this regional market can be attributed to the presence of major players operating in the IHC market in the US, rising incidence of cancer and infectious diseases, and the increasing adoption of companion diagnostic assay kits.

The prominent players operating in the IHC market are F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), Danaher Corporation (US), PHC Holding Corporation (Japan), Biocare Medical, LLC. (US), and Merck KGaA (Germany).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

Comments

comments

You may also like...